skip to Main Content
Home » UK Shares » Sareum Holdings: CEO Tim Mitchell talks about his COVID research pipeline

Sareum Holdings: CEO Tim Mitchell talks about his COVID research pipeline


Early-stage pharma developer Sareum Holdings (AIM:SAR) is making good progress on its pipeline of projects, justifying the share price rise increases earlier this year.

With Covid spreading damage particularly hard in the UK in the early months of 2021 shares rocketed to 8.85 pence in August – from 220 pence at the end of 2020 – as investors' focus zeroed in on the company’s research on a molecule that could be used to treat breathing complications caused by the virus.


Want to read more? Sign up for your free 30 day trial below or find out more about Armchair Trader Plus+ here.

Log In or Sign Up to Armchair Trader+

Already a member? Log in here:

Not a member yet? Sign up for your free trial or check out the benefits of membership.

Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader+ for further details on the benefits of becoming a member.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

Invest in UK Shares with these FCA Regulated brokers

Hargreaves LansdownIGInteractive InvestorCharles StanleyYou Invest

The Armchair Trader's 'How to' Guides

Stocks in Focus

We think these smaller companies represent significant growth stories. Read our in-depth reports.

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Back To Top